frontiers | Frontiers in Drug Safety and Regulation

SPECIALTY GRAND CHALLENGE
published: 05 April 2022
doi: 10.3389/fdsfr.2022.881556

Current Status and Future Challenges in the Treatment of Rheumatic Diseases

Enrique R. Soriano *

Rheumatology Unit, Internal Medicine Services, Insituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Keywords: treatment rheumatic diseases, biologics, treat to target, precision medicine, prevention

INTRODUCTION

In the last decades, the treatment of rheumatic diseases has been revolutionized by a deeper understanding of their physiopathology, the introduction of several new treatments with different targets, and the comprehension of the importance of a strategic approach to these diseases.

STRATEGIC APPROACH TO TREATMENT

The strategic approach is probably as important as the incorporation of new drugs and their new mechanism of action. The strategic approach to rheumatic disease includes early diagnosis and early treatment, remission as the main objective of treatment, frequent assessment of disease activity using validated measurements tools, adjustment of treatment when the objective is not achieved (called treat to target strategy), and finally, shared therapeutic decisions with the patients. Each one of these strategic points are not only intuitively appealing, but also based on good evidence.

Early Diagnosis and Treatment

That early diagnosis is associated with better long-term outcomes has been proved for rheumatoid arthritis (RA) (Aletaha and Smolen, 2018), psoriatic arthritis (PsA) (Tillett et al., 2013), spondyloarthritis (SpA) (Barnett et al., 2020), systemic lupus erythematosus (SLE) (Sebastiani et al., 2016), systemic sclerosis (SSc) (Minier et al., 2014), and antiphospholipid syndrome (APS) (Tektonidou et al., 2019), to mention some. To achieve early diagnosis and treatment of rheumatic diseases are the objectives of many efforts in the rheumatology community.

Remission as Treatment Goal

To aim for remission as a treatment target has been stressed by multiple recommendations in different diseases such as RA (Smolen et al., 2020), PsA (Coates et al., 2014; Gossec et al., 2020), SpA (van der Heijde et al., 2017), SLE (Pons-Estel et al., 2018), etc., although the definition of remission has been elusive for some multidimensional diseases such as SLE (Aringer et al., 2019) and PsA (Acosta Felquer et al., 2014; Soriano, 2015). Nowadays almost all rheumatologists are aiming for remission when treating their patients and share this objective with their patients.

Treat to Target

The concept of treat to target has evolved over time for different rheumatic diseases (Smolen, 2019). The treat to target strategy has been well proved by randomized clinical trials only in a few diseases such as RA (Salomon-Escoto and Kay, 2019) and PsA (Coates and Helliwell, 2015), has been challenged in others such as SpA (Molto et al., 2021), and has indirect evidence in SLE (Aringer et al., 2019) gout (Perez-Ruiz and Dalbeth, 2019), and inflammatory myopathies (Vencovsky et al., 2019).

OPEN ACCESS

Edited and reviewed by:
Gianluca Trifirò,
University of Verona, Italy

***Correspondence:**
Enrique R. Soriano
enrique.soriano@hospitalitaliano.org.ar

Received: *22 February 2022*
Accepted: *07 March 2022*
Published: *05 April 2022*

Citation:
Soriano ER (2022) Current Status and Future Challenges in the Treatment of Rheumatic Diseases. Front. Drug. Saf. Regul. 2:881556. doi: 10.3389/fdsfr.2022.881556

In any case, the basic principles on which the strategy is built stand for all these diseases. Those principles are the use of measures that allow the assessment of disease activity and that correlate with disease progression and physical function; and the availability of effective treatments able to induce remission which in turn will influence damage progression and provide dramatic advantages in outcomes (Smolen, 2019). Without good measurement tools of disease activity and effective treatments capable to achieve the goal of remission, the treat to target strategy is simply not possible.

Shared Therapeutic Decisions

It has been shown that less patient participation in clinical decisions is associated with less satisfaction with the decision process (Nota et al., 2014). Low patient satisfaction on the other hand is associated with poorer outcomes and lower adherence to therapy (Anghel et al., 2018). Despite this knowledge, there is still a lot of medical education needed to achieve ideal levels of shared therapeutic decisions in daily clinical practice (Mathijssen et al., 2020).

CURRENT CHALLENGES FOR RHEUMATOLOGISTS

Drug Safety

Rheumatologists have been lucky in the last decades because there has been enormous resource investment into the development of new drugs with many different mechanisms of action. This resulted in huge changes in the outcomes and quality of life of patients. The mandatory study design for the approval of new drugs is the randomized clinical trial (RCT). Some of the limitations of RCTs are their short duration (3–5 years) that does not give correct estimates of the lifetime effects of the interventions, and the inclusion of highly selected patients that are not representative of real-world populations (Kostis and Dobrzynski, 2020). This raises the question of what the effectiveness of this treatment in real life would be, and of utmost importance, what will be the long-term and generalizable safety of the developed drug?

To have safe drugs for the treatment of rheumatic diseases is one of the current challenges of this specialty and one of the major concerns of patients. People's perceptions of their medications and their safety heavily influence adherence and drug persistence (Anghel et al., 2018).

Drug surveillance and real-life data are of extreme importance if some infrequent adverse events are going to be detected. There are a good number of examples where adverse events in drugs only clearly appeared once the medication was approved and used in real life. The association of tumor necrosis factor alpha inhibitors (TNFi) with tuberculosis was not detected during clinical trials, but only reported after these drugs were approved and used in real life in patients with Crohn's disease and rheumatoid arthritis (Keane et al., 2001). The increased risk of lower gastrointestinal perforation in patients with rheumatoid arthritis treated with tocilizumab, although seen during clinical trials (Schiff et al., 2011), was only more clearly reported after approval and with observational studies (Gout et al., 2011). Very recently, data emerged from observational and randomized clinical trials related to increased lipids levels and cardiovascular risk and thrombosis in patients with rheumatoid arthritis treated with Janus kinases inhibitors (JAKi) (van der Heijde et al., 2019).

In fact, based on the results of a 4-year randomized, open-label, noninferiority, post authorization, safety end-point trial, in which patients with active rheumatoid arthritis despite methotrexate received tofacitinib twice daily or a subcutaneous tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab) (Kremer et al., 2021), the Food and Drug Administration (FDA) in the US issued a black-box warning for JAK inhibitors and changed the indications for tofacitinib and upadacitinib from incomplete response to methotrexate to incomplete response to a TNF inhibitor.

Several long-term follow-up studies, surveillance studies, and real-world data have not found an increased risk of cardiovascular events and cancer in patients with rheumatoid arthritis treated with JAK inhibitors, but usually these studies lack a control group (Charles-Schoeman et al., 2016; Cohen et al., 2020; Mease et al., 2020).

Safety issues and safety concerns and their relationship with regulatory agencies are far from solved, and would need much more research and publications, for which dedicated journals are welcomed.

Precision Medicine

Despite the many advances made in the past three decades on the knowledge of the pathogenesis of many rheumatic diseases and the identification of several novel therapeutic targets and treatments, we have been unable to identify which treatment will be of more benefit for each patient, and in most cases, treatment recommendations are based on a trial-and-error approach.

Predicting which treatment will be efficacious for an individual patient or disease domain involvement would be extremely valuable both for patients and physicians.

However this does not mean the creation of a drug or medical device that is unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their response to a specific treatment, as stated by the National Research Council of the US National Academies FDA, (2011).

Some genetic, serum-soluble, cellular, and tissue biomarkers have been identified that help better classify subpopulations in different rheumatic diseases and might predict treatment response in many of them, however those findings have not yet been implemented in daily clinical practice (Demirkaya et al., 2019; Jadon et al., 2020; Wampler Muskardin et al., 2020). More clear and easy approaches are needed. For example, in rheumatoid arthritis with the exception of a few clinical situations (Poddubnyy, 2021) (e.g., superiority of tocilizumab compared with adalimumab—a TNF inhibitor—in patients requiring monotherapy (Gabay et al., 2013); somewhat better response to abatacept compared with adalimumab in patients with poor prognostic factors, including a high concentration of anticitrullinated protein antibodies (Fleischmann et al., 2019);

and an overall better response to rituximab in patients who are seropositive compared with patients who have seronegative rheumatoid arthritis (Courvoisier et al., 2021)), there are currently no markers that could be used for a precision medicine approach in clinical practice.

There is also some rationality on the theory that response to a specific drug could be related to the molecular pathway targeted by the drug in the synovium. Using this theoretical framework, the findings of studies linking response to therapy with synovial changes provide promising perspectives on bridging the gap to precision medicine in RA (Triaille and Lauwerys, 2019). However as synovial biopsy is an invasive procedure, the information gain should justify its use in clinical practice (Poddubnyy, 2021).

In psoriatic arthritis, a single group reported good predictive response to therapy using phenotyping of peripheral blood lymphocytes by flow cytometry through the identification of intracellular signals, and classified psoriatic arthritis patients in four groups based on the lymphocyte phenotypes found (Miyagawa and Tanaka, 2020). However, the technique is not available in clinical practice and features need to be validated with a larger number of patients and by other research groups.

In lupus, high levels of type I interferon (IFN), that presented in 50% of patients, have been associated with several genetic factors and with cutaneous and renal manifestations and the presence of autoantibodies, such as anti-Ro, anti-Smith (anti-Sm), anti-RNP, and anti-dsDNA antibodies (Wampler Muskardin et al., 2020). Clinical trials of monoclonal antibodies targeting type I IFN receptors have been published (Furie et al., 2017; Morand et al., 2020), and anifrolumab has been approved by the FDA for the treatment of patients with lupus, although a clear subpopulation of patients especially susceptible to this treatment has not been identified yet.

In summary, we are still far away from practicing precision medicine in rheumatology. Strategy studies with characterization of the disease or disease subtypes might help to identify specific predictors of response and non-response and to develop individualized treatment approaches.

Prevention of Rheumatic Diseases

It is likely there would be no argument that preventing a disease is better than treating it, especially in rheumatic diseases where no cure has been discovered once the disease is apparent. The World Health Organization developed recommendations for disease screening and prevention. Overall, these recommendations suggest that diseases targeted for screening and prevention should have an important impact on health, an identifiable asymptomatic (or minimally symptomatic) period, during which individuals at high-risk for future disease can be accurately identified, and that there be available an effective means for preventing the further evolution of disease (Wilson and Jungner, 1968; Finckh and Deane, 2014).

Prevention strategies are typically categorized into primary, secondary, and tertiary interventions (Finckh and Deane, 2014). With primary prevention, researchers try to avoid the development of disease by eliminating specific risk factors or increasing an individual´s resistance to the condition, similar to vaccination against infections (Finckh and Deane, 2014). Secondary prevention strategies attempt to reduce progression from a latent or asymptomatic phase of disease to symptomatic disease, trying to interrupt mechanisms of disease development, as done by early identification of cancers through programs such as mammograms and colonoscopies (Finckh and Deane, 2014). The aim of tertiary prevention is to delay or limit the impact of an established disease, and this is how clinicians currently deal with most rheumatic diseases (Finckh and Deane, 2014).

As the knowledge on risk factors for the development of rheumatic diseases grows, it would be advantageous to introduce primary prevention in rheumatic diseases.

Environmental risk factors are of great interest for a preventive strategy of rheumatic diseases, as they are potentially modifiable.

Smoking and other airway stimuli such as silica dust act as environmental factors for the development of antibodies to the citrullinated protein antigen (ACPA)-positive subset of rheumatoid arthritis (Klareskog et al., 2010). Avoiding these risk factors is a practicable primary prevention strategy for RA (Liu et al., 2019).

It has been shown that most patients with RA develop ACPA antibodies many years before development of the disease (Nielen et al., 2004). In some individuals the presence of ACPAs may be accompanied by increased levels of proinflammatory cytokines in blood, and this stage may be followed by non-specific signs of arthritis and eventually by development of polyarthritis fulfilling diagnostic criteria (Finckh and Deane, 2014). All this information provides a "window of opportunity" for secondary prevention. Although an exciting theory, attempts to prevent the development of RA in clinical trials have been unsuccessful so far (Deane and Holers, 2021; O'Neil and Deane, 2021).

In lupus, smoking has also been found to be a risk factor, although not as extensively studied as in RA.

Sunlight is otherwise the most well-known exposure that enhances disease flare-ups, and most probably lupus development too (Klareskog et al., 2010). Hydroxychloroquine has a proven effect in tertiary prevention in lupus and perhaps some effect even in secondary prevention (Finckh and Deane, 2014).

In neonatal cardiac heart block associated with the presence of high antibody titers against the Ro52 protein in women with SLE and Sjogren's syndrome, it is possible to prevent the damage to the fetal heart by treating the mother with high doses of steroids between weeks 20–24 of gestation, another example of primary prevention.

Several modifiable risk factors have been identified in psoriatic arthritis (Soriano, 2019). Evidence that weight loss is beneficial for primary prevention of psoriasis and PsA development is accumulating, and difficult to dispute (Soriano, 2019; Green et al., 2020). For secondary prevention, there is some evidence that identifying and treating subclinical enthesitis in patients with psoriasis might prevent the development of psoriatic arthritis (Soriano, 2019). Finally, there is some controversy on whether effective treatment with biologics of patients with psoriasis might be able to prevent the development of psoriatic arthritis in these patients (Soriano, 2019; Acosta Felquer et al., 2022; Meer et al., 2022).

In summary, new strategies including early diagnosis and treatment, the treat to target approach, remission as the treatment objective, and patients' participation in therapy decisions, plus the development of new effective treatments have changed the expectations of rheumatologists and patients alike. There are still some challenges such as long-term safety of current treatments, and a more individualized and effective treatment of different subgroups of patients. The future is likely the prevention of the development of rheumatic diseases.

AUTHOR CONTRIBUTIONS

ERS wrote the manuscript, and approved it for submission.

REFERENCES

Acosta Felquer, M. L., Ferreyra Garrott, L., Marin, J., Catay, E., Scolnik, M., Scaglioni, V., et al. (2014). Remission Criteria and Activity Indices in Psoriatic Arthritis. *Clin. Rheumatol.* 33, 1323–1330. doi:10.1007/s10067-014-2626-y

Acosta Felquer, M. L., Logiudice, L., Galimberti, M. L., Rosa, J., Mazzuoccolo, L., and Soriano, E. R. (2022). Treating the Skin with Biologics in Patients with Psoriasis Decreases the Incidence of Psoriatic Arthritis. *Ann. Rheum. Dis.* 81, 74–79. doi:10.1136/annrheumdis-2021-220865

Aletaha, D., and Smolen, J. S. (2018). Diagnosis and Management of Rheumatoid Arthritis. *JAMA* 320, 1360–1372. doi:10.1001/jama.2018.13103

Anghel, L.-A., Farcaș, A., and Oprean, R. (2018). Medication Adherence and Persistence in Patients with Autoimmune Rheumatic Diseases: a Narrative Review. *Patient Prefer Adherence* 12, 1151–1166. doi:10.2147/ppa.s165101

Aringer, M., Leuchten, N., and Schneider, M. (2019). Treat to Target in Systemic Lupus Erythematosus. *Rheum. Dis. Clin. North America* 45, 537–548. doi:10.1016/j.rdc.2019.07.004

Barnett, R., Ingram, T., and Sengupta, R. (2020). Axial Spondyloarthritis 10 Years on: Still Looking for the Lost Tribe. *Rheumatology (Oxford)* 59, iv25–iv37. doi:10.1093/rheumatology/keaa472

Charles-Schoeman, C., Wicker, P., Gonzalez-Gay, M. A., Boy, M., Zuckerman, A., Soma, K., et al. (2016). Cardiovascular Safety Findings in Patients with Rheumatoid Arthritis Treated with Tofacitinib, an Oral Janus Kinase Inhibitor. *Semin. Arthritis Rheum.* 46, 261–271. doi:10.1016/j.semarthrit.2016.05.014

Coates, L. C., and Helliwell, P. S. (2015). Treat to Target in Psoriatic Arthritis-Evidence, Target, Research Agenda. *Curr. Rheumatol. Rep.* 17, 517. doi:10.1007/s11926-015-0517-0

Coates, L. C., Ritchlin, C. T., and Kavanaugh, A. F. (2014). GRAPPA Treatment Recommendations: an Update from the GRAPPA 2013 Annual Meeting. *J. Rheumatol.* 41, 1237–1239. doi:10.3899/jrheum.140179

Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., et al. (2020). Long-term Safety of Tofacitinib up to 9.5 Years: a Comprehensive Integrated Analysis of the Rheumatoid Arthritis Clinical Development Programme. *RMD Open* 6. doi:10.1136/rmdopen-2020-001395

Courvoisier, D. S., Chatzidionysiou, K., Mongin, D., Lauper, K., Mariette, X., Morel, J., et al. (2021). The Impact of Seropositivity on the Effectiveness of Biologic Anti-rheumatic Agents: Results from a Collaboration of 16 Registries. *Rheumatology (Oxford)* 60, 820–828. doi:10.1093/rheumatology/keaa393

Deane, K. D., and Holers, V. M. (2021). Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift. *Arthritis Rheumatol.* 73, 181–193. doi:10.1002/art.41417

Demirkaya, E., Arici, Z. S., Romano, M., Berard, R. A., and Aksentijevich, I. (2019). Current State of Precision Medicine in Primary Systemic Vasculitides. *Front. Immunol.* 10, 2813. doi:10.3389/fimmu.2019.02813

FDA Drug Safety Communication 2021. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. (Washington (DC): National Academies Press). Available at: https://www.ncbi.nlm.nih.gov/books/NBK91503/.

FDA (2011). *Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*. Washington (DC): National Academies Press.

Finckh, A., and Deane, K. D. (2014). Prevention of Rheumatic Diseases. *Rheum. Dis. Clin. North America* 40, 771–785. doi:10.1016/j.rdc.2014.07.010

Fleischmann, R., Weinblatt, M., Ahmad, H., Maldonado, M. A., Alemao, E., Ye, J., et al. (2019). Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis with Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). *Rheumatol. Ther.* 6, 559–571. doi:10.1007/s40744-019-00174-7

Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., et al. (2017). Anifrolumab, an Anti-interferon-α Receptor Monoclonal Antibody, in Moderate-To-Severe Systemic Lupus Erythematosus. *Arthritis Rheumatol.* 69, 376–386. doi:10.1002/art.39962

Gabay, C., Emery, P., Van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., et al. (2013). Tocilizumab Monotherapy versus Adalimumab Monotherapy for Treatment of Rheumatoid Arthritis (ADACTA): a Randomised, Double-Blind, Controlled Phase 4 Trial. *The Lancet* 381, 1541–1550. doi:10.1016/s0140-6736(13)60250-0

Gossec, L., Baraliakos, X., Kerschbaumer, A., De Wit, M., Mcinnes, I., Dougados, M., et al. (2020). EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update. *Ann. Rheum. Dis.* 79, 700–712. doi:10.1136/annrheumdis-2020-217159

Gout, T., Östör, A. J. K., and Nisar, M. K. (2011). Lower Gastrointestinal Perforation in Rheumatoid Arthritis Patients Treated with Conventional DMARDs or Tocilizumab: a Systematic Literature Review. *Clin. Rheumatol.* 30, 1471–1474. doi:10.1007/s10067-011-1827-x

Green, A., Shaddick, G., Charlton, R., Snowball, J., Nightingale, A., Smith, C., et al. (2020). Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis. *Br. J. Dermatol.* 182, 714–720. doi:10.1111/bjd.18227

Jadon, D. R., Stober, C., Pennington, S. R., and Fitzgerald, O. (2020). Applying Precision Medicine to Unmet Clinical Needs in Psoriatic Disease. *Nat. Rev. Rheumatol.* 16, 609–627. doi:10.1038/s41584-020-00507-9

Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., et al. (2001). Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α-Neutralizing Agent. *N. Engl. J. Med.* 345, 1098–1104. doi:10.1056/nejmoa011110

Klareskog, L., Gregersen, P. K., and Huizinga, T. W. J. (2010). Prevention of Autoimmune Rheumatic Disease: State of the Art and Future Perspectives. *Ann. Rheum. Dis.* 69, 2062–2066. doi:10.1136/ard.2010.142109

Kostis, J. B., and Dobrzynski, J. M. (2020). Limitations of Randomized Clinical Trials. *Am. J. Cardiol.* 129, 109–115. doi:10.1016/j.amjcard.2020.05.011

Kremer, J. M., Bingham, C. O., 3rd, Cappelli, L. C., Greenberg, J. D., Madsen, A. M., Geier, J., et al. (2021). Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. *ACR Open Rheuma* 3, 173–184. doi:10.1002/acr2.11232

Liu, X., Tedeschi, S. K., Barbhaiya, M., Leatherwood, C. L., Speyer, C. B., Lu, B., et al. (2019). Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses' Health Studies. *Arthritis Care Res.* 71, 914–924. doi:10.1002/acr.23837

Mathijssen, E. G. E., Vriezekolk, J. E., Popa, C. D., and Van Den Bemt, B. J. F. (2020). Shared Decision Making in Routine Clinical Care of Patients with Rheumatoid Arthritis: an Assessment of Audio-Recorded Consultations. *Ann. Rheum. Dis.* 79, 170–175. doi:10.1136/annrheumdis-2019-216137

Mease, P., Charles-Schoeman, C., Cohen, S., Fallon, L., Woolcott, J., Yun, H., et al. (2020). Incidence of Venous and Arterial Thromboembolic Events Reported in the Tofacitinib Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Development Programmes and from Real-World Data. *Ann. Rheum. Dis.* 79, 1400–1413. doi:10.1136/annrheumdis-2019-216761

Meer, E., Merola, J. F., Fitzsimmons, R., Love, T. J., Wang, S., Shin, D., et al. (2022). Does Biologic Therapy Impact the Development of PsA Among Patients with Psoriasis? *Ann. Rheum. Dis.* 81, 80–86. doi:10.1136/annrheumdis-2021-220761

Minier, T., Guiducci, S., Bellando-Randone, S., Bruni, C., Lepri, G., Czirják, L., et al. (2014). Co-Workers, E. & Co-workers, EPreliminary Analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR Multicentre Study: Evidence for Puffy Fingers as a Pivotal Sign for Suspicion of Systemic Sclerosis. *Ann. Rheum. Dis.* 73, 2087–2093. doi:10.1136/annrheumdis-2013-203716

Miyagawa, I., and Tanaka, Y. (2020). Is Precision Medicine Possible in Rheumatic Diseases? Lessons from Selective Use of Targeted Therapies in Patients with Psoriatic Arthritis. *Expert Rev. Clin. Immunol.* 16, 199–206. doi:10.1080/1744666x.2019.1706484

Molto, A., López-Medina, C., Van Den Bosch, F. E., Boonen, A., Webers, C., Dernis, E., et al. (2021). Efficacy of a Tight-Control and Treat-To-Target Strategy in Axial Spondyloarthritis: Results of the Open-Label, Pragmatic, Cluster-Randomised TICOSPA Trial. *Ann. Rheum. Dis.* 80, 1436–1444. doi:10.1136/annrheumdis-2020-219585

Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., et al. (2020). Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N. Engl. J. Med.* 382, 211–221. doi:10.1056/nejmoa1912196

Nielen, M. M. J., Van Schaardenburg, D., Reesink, H. W., Van De Stadt, R. J., Van Der Horst-Bruinsma, I. E., De Koning, M. H. M. T., et al. (2004). Specific Autoantibodies Precede the Symptoms of Rheumatoid Arthritis: a Study of Serial Measurements in Blood Donors. *Arthritis Rheum.* 50, 380–386. doi:10.1002/art.20018

Nota, I., Drossaert, C. H., Taal, E., Vonkeman, H. E., and Van De Laar, M. A. (2014). Patient Participation in Decisions about Disease Modifying Anti-rheumatic Drugs: a Cross-Sectional Survey. *BMC Musculoskelet. Disord.* 15, 333. doi:10.1186/1471-2474-15-333

O'Neil, L. J., and Deane, K. D. (2021). Striking a Balance in Rheumatoid Arthritis Prevention Trials. *Nat. Rev. Rheumatol.* 17, 385–386. doi:10.1038/s41584-021-00627-w

Perez-Ruiz, F., and Dalbeth, N. (2019). Gout. *Rheum. Dis. Clin. North America* 45, 583–591. doi:10.1016/j.rdc.2019.08.001

Poddubnyy, D. (2021). Precision Medicine in Rheumatology: Are We Getting Closer? *The Lancet* 397, 258–259. doi:10.1016/s0140-6736(20)32652-0

Pons-Estel, B. A., Bonfa, E., Soriano, E. R., Cardiel, M. H., Izcovich, A., Popoff, F., et al. (2018). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). *Ann. Rheum. Dis.* 77, 1549–1557. doi:10.1136/annrheumdis-2018-213512

Salomon-Escoto, K., and Kay, J. (2019). The "Treat to Target" Approach to Rheumatoid Arthritis. *Rheum. Dis. Clin. North America* 45, 487–504. doi:10.1016/j.rdc.2019.06.001

Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D., and Van Vollenhoven, R. F. (2011). Integrated Safety in Tocilizumab Clinical Trials. *Arthritis Res. Ther.* 13, R141. doi:10.1186/ar3455

Sebastiani, G. D., Prevete, I., Iuliano, A., and Minisola, G. (2016). The Importance of an Early Diagnosis in Systemic Lupus Erythematosus. *Isr. Med. Assoc. J.* 18, 212–215.

Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., et al. (2020). EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. *Ann. Rheum. Dis.* 79, 685–699. doi:10.1136/annrheumdis-2019-216655

Smolen, J. S. (2019). Treat to Target in Rheumatology. *Rheum. Dis. Clin. North America* 45, 477–485. doi:10.1016/j.rdc.2019.07.001

Soriano, E. R. (2015). Defining Remission in Psoriatic Arthritis: Are We Getting Closer? *J. Rheumatol.* 42, 907–908. doi:10.3899/jrheum.150331

Soriano, E. R. (2019). Interventions on Modifiable Risk Factors for the Development of Psoriatic Arthritis. *Curr. Treat. Options. Rheum.* 5, 313–325. doi:10.1007/s40674-019-00135-9

Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., et al. (2019). EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults. *Ann. Rheum. Dis.* 78, 1296–1304. doi:10.1136/annrheumdis-2019-215213

Tillett, W., Jadon, D., Shaddick, G., Cavill, C., Korendowych, E., De Vries, C. S., et al. (2013). Smoking and Delay to Diagnosis Are Associated with Poorer Functional Outcome in Psoriatic Arthritis. *Ann. Rheum. Dis.* 72, 1358–1361. doi:10.1136/annrheumdis-2012-202608

Triaille, C., and Lauwerys, B. R. (2019). Synovial Tissue: Turning the Page to Precision Medicine in Arthritis. *Front. Med.* 6, 46. doi:10.3389/fmed.2019.00046

Van der Heijde, D., Strand, V., Tanaka, Y., Keystone, E., Kremer, J., Zerbini, C. A. F., et al. (2019). Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes from a Twenty-Four-Month, Phase III Study. *Arthritis Rheumatol.* 71, 878–891. doi:10.1002/art.40803

Van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van Den Bosch, F., Sepriano, A., et al. (2017). 2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis. *Ann. Rheum. Dis.* 76, 978–991. doi:10.1136/annrheumdis-2016-210770

Vencovský, J., Alexanderson, H., and Lundberg, I. E. (2019). Idiopathic Inflammatory Myopathies. *Rheum. Dis. Clin. North America* 45, 569–581. doi:10.1016/j.rdc.2019.07.006

Wampler Muskardin, T. L., Paredes, J. L., Appenzeller, S., and Niewold, T. B. (2020). Lessons from Precision Medicine in Rheumatology. *Mult. Scler.* 26, 533–539. doi:10.1177/1352458519884249

Wilson, J. M., and Jungner, Y. G. (1968). Principles and Practice of Mass Screening for Disease. *Bol Oficina Sanit Panam* 65, 281–393.

Conflict of Interest: ES is an advisor for AbbVie, Janssen, Novartis, Pfizer, and Roche; grant/research support from AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB; speaker/received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.